Clinical Trial: Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07355868) titled 'Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy' on Jan. 12.

Brief Summary: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND007 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. A prospective, single-arm, dose-escalation exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of different doses of REGEN...